Lv3
276 积分 2020-08-11 加入
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
12天前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
13天前
已完结
Establishing the Pharmacokinetics of Genetic Vaccines is Essential for Maximising their Safety and Efficacy
16天前
已完结
A Comprehensive review on Pharmacokinetic Studies of Vaccines: Impact of delivery route, carrier-and its modulation on immune response
16天前
已完结
A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials
2个月前
已完结
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
4个月前
已完结
Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors
4个月前
已完结
Assessment of food effects during clinical development
4个月前
已完结
Free Drug Theory – No Longer Just a Hypothesis?
4个月前
已完结
Use of log−log survival function in modeling time-covariate interactions in Cox regression
4个月前
已完结
皖公网安备34019202002308
